- Home
- SUPN vs BEAM Comparison
SUPN vs BEAM Comparison
Compare SUPN & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SUPN
- BEAM
- Stock Information
- Founded
- SUPN 2005
- BEAM 2017
- Country
- SUPN United States
- BEAM United States
- Employees
- SUPN N/A
- BEAM N/A
- Industry
- SUPN Biotechnology: Pharmaceutical Preparations
- BEAM Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SUPN Health Care
- BEAM Health Care
- Exchange
- SUPN Nasdaq
- BEAM Nasdaq
- Market Cap
- SUPN 2.1B
- BEAM 1.9B
- IPO Year
- SUPN 2012
- BEAM 2020
- Fundamental
- Price
- SUPN $37.74
- BEAM $23.44
- Analyst Decision
- SUPN Hold
- BEAM Buy
- Analyst Count
- SUPN 1
- BEAM 10
- Target Price
- SUPN $36.00
- BEAM $47.67
- AVG Volume (30 Days)
- SUPN 376.5K
- BEAM 1.3M
- Earning Date
- SUPN 02-25-2025
- BEAM 02-25-2025
- Dividend Yield
- SUPN N/A
- BEAM N/A
- EPS Growth
- SUPN 130.79
- BEAM N/A
- EPS
- SUPN 1.07
- BEAM N/A
- Revenue
- SUPN $651,972,000.00
- BEAM $349,643,000.00
- Revenue This Year
- SUPN $7.82
- BEAM N/A
- Revenue Next Year
- SUPN N/A
- BEAM $10.82
- P/E Ratio
- SUPN $35.28
- BEAM N/A
- Revenue Growth
- SUPN 6.79
- BEAM 328.73
- 52 Week Low
- SUPN $25.53
- BEAM $20.84
- 52 Week High
- SUPN $39.37
- BEAM $49.50
- Technical
- Relative Strength Index (RSI)
- SUPN 57.78
- BEAM 38.04
- Support Level
- SUPN $36.48
- BEAM $22.50
- Resistance Level
- SUPN $38.68
- BEAM $28.39
- Average True Range (ATR)
- SUPN 1.06
- BEAM 1.68
- MACD
- SUPN 0.09
- BEAM -0.41
- Stochastic Oscillator
- SUPN 68.46
- BEAM 15.05
About SUPN Supernus Pharmaceuticals Inc.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. The Company's diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.
About BEAM Beam Therapeutics Inc.
Beam Therapeutics Inc is a biotechnology company engaged in creating genetic medicines based on its base editing technology. This technology enables a new class of genetic medicines that targets a single base in the genome without making a double-stranded break in the DNA. The company's portfolio comprises Gene Correction, Gene Modification, Gene Activation, Gene Silencing, and Multiplex Editing. The company's pipeline programs consist of BEAM-101, ESCAPE, BEAM-302, BEAM-301, and BEAM-201.